PfizerPFE
PFE
0
Funds holding %
of 6,780 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
26% more funds holding in top 10
Funds holding in top 10: 31 [Q2] → 39 (+8) [Q3]
7% more first-time investments, than exits
New positions opened: 188 | Existing positions closed: 175
4% more repeat investments, than reductions
Existing positions increased: 1,209 | Existing positions reduced: 1,167
0% more funds holding
Funds holding: 2,822 [Q2] → 2,835 (+13) [Q3]
1% less capital invested
Capital invested by funds: $108B [Q2] → $107B (-$981M) [Q3]
2.62% less ownership
Funds ownership: 67.33% [Q2] → 64.71% (-2.62%) [Q3]
38% less call options, than puts
Call options by funds: $2.51B | Put options by funds: $4.05B
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$25
2%
downside
Avg. target
$40
57%
upside
High target
$45
76%
upside
7 analyst ratings
5 positive
71%
1 neutral
14%
1 negative
14%
Wolfe Research Alexandria Hammond 43% 1-year accuracy 3 / 7 met price target | 2%downside $25 | Underperform Initiated | 15 Nov 2024 |
Cantor Fitzgerald Louise Chen 30% 1-year accuracy 43 / 141 met price target | 76%upside $45 | Overweight Reiterated | 25 Oct 2024 |
Cantor Fitzgerald Louise Chen 30% 1-year accuracy 43 / 141 met price target | 76%upside $45 | Overweight Reiterated | 23 Oct 2024 |
Bernstein Courtney Breen 0 / 0 met price target | 25%upside $32 | Market Perform Initiated | 17 Oct 2024 |
Cantor Fitzgerald Louise Chen 30% 1-year accuracy 43 / 141 met price target | 76%upside $45 | Overweight Reiterated | 3 Oct 2024 |
Financial journalist opinion
Based on 102 articles about PFE published over the past 30 days
Positive
Zacks Investment Research
1 day ago
5 Low Price-to-Book Value Stocks to Buy in December
The P/B ratio helps to identify low-priced stocks with high growth prospects. GM, SEM, AXS, ZIM and PFE are some such stocks.
Positive
The Motley Fool
1 day ago
3 Magnificent Dividend Stocks With Yields Above 6% to Buy in December
The past couple of years have been terrific for stocks, with the benchmark S&P 500 index up a whopping 57.1% since the end of 2022. However, after the index's two-year bull run, it's getting harder to find quality dividend stocks that offer satisfying yields.
Positive
Seeking Alpha
1 day ago
Mastercard, Broadcom, Pfizer Among Two Dozen Companies To Announce Dividend Increases In December
This is my latest article where I provide predictions of upcoming dividend increases from companies with long-term dividend growth histories. It'll be a busy December for dividend growth investors, with 25 companies announcing their annual increases, with good increases expected from digital payment company Mastercard and semiconductor company Broadcom. Investors were rewarded with increases in the last two weeks of November, including double-digit boosts from precious metals miner Royal Gold and specialty insurer Assurant.
Positive
The Motley Fool
2 days ago
3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later
You don't have to be an income investor to like dividends. Many billionaires who definitely don't need income still have dividend stocks in their portfolios.
Positive
Zacks Investment Research
3 days ago
4 Best Value Stocks to Invest in This December for Strong Returns
Value investing is essentially about selecting stocks that are cheap but fundamentally sound. TSN, AXS, PFE & GM boast a low P/CF ratio.
Positive
The Motley Fool
4 days ago
Is This a New Reason to Buy Pfizer Stock Hand Over Fist?
Despite Pfizer's (PFE 0.23%) recent struggles with falling earnings and a bid by an activist investor to unseat its leadership, the pharma juggernaut is still actively advancing its core priorities and giving investors plenty of reasons to consider buying its stock while it's cheap.
Positive
Zacks Investment Research
5 days ago
Are Investors Undervaluing Pfizer (PFE) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Positive
MarketBeat
5 days ago
Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch
Leading vaccine makers like Eli Lilly and Co. NYSE: LLY, Pfizer Inc. NYSE: PFE, and AstraZeneca plc NASDAQ: AZN may have faded from the spotlight since the peak of the COVID-19 pandemic, but now there is reason to expect renewed interest. As investors look ahead to the second Trump administration, the incoming president's nomination of outspoken vaccine critic Robert F.
Positive
Seeking Alpha
5 days ago
5 Blue Chips Yielding Over 7% I'm Considering Buying, And So Should You
I'm seeking 6%-plus yielding blue-chip bargains for my family's portfolio, with a focus on long-term income growth and minimal volatility. My ZEUS Family portfolio strategy involves annual rebalancing and screening for undervalued, high-quality stocks with strong fundamentals and risk management. I'm considering five blue-chip alternatives to Enbridge, offering 7% yields, 6-7% annual dividend growth, and 13-14% long-term income growth.
Neutral
The Motley Fool
5 days ago
Is Pfizer Stock in Trouble?
One stock that just can't seem to catch a break of late is Pfizer (PFE 0.23%). Even though it posted some decent earnings numbers, investors can't shake the fear that the business is facing daunting headwinds that could send its $145 billion valuation lower in the months and years ahead.
Charts implemented using Lightweight Charts™